CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Exclusive License Agreement • July 16th, 2021 • Candel Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledJuly 16th, 2021 Company Industry JurisdictionThis Exclusive License Agreement (hereinafter referred to as this “Agreement”), effective as March 1, 2014 (the “Effective Date”), is entered into by and between Advantagene, Inc., a corporation duly incorporated under the laws of Delaware and having a place of business at 440 Lexington Street, Auburndale, MA (“Licensor”), and Ventagen, LLC., a Massachusetts limited liability company, having a place of business at 160 Paulson Road, Waban MA (the “Company”).
EXCLUSIVE LICENSE AGREEMENT between ADVANTAGENE, INC. and VENTAGEN, L.L.C.Exclusive License Agreement • June 25th, 2021 • Candel Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledJune 25th, 2021 Company Industry JurisdictionThis Exclusive License Agreement (hereinafter referred to as this “Agreement”), effective as March 1, 2014 (the “Effective Date”), is entered into by and between Advantagene, Inc., a corporation duly incorporated under the laws of Delaware and having a place of business at 440 Lexington Street, Auburndale, MA (“Licensor”), and Ventagen, LLC., a Massachusetts limited liability company, having a place of business at 160 Paulson Road, Waban MA (the “Company”).